301257.SHE SMO ClinPlus Co. Ltd.
- Market cap
- CNY 2.67B
- P/E
- 46.9x
- P/B
- 2.11x
- ROE
- 0.4%
- Dividend yield
- 0.50%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 301257.SHE undervalued?
Graham number301257.SHE trades 109.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SMO ClinPlus Co. Ltd. fundamental analysis
No fundamental analysis for SMO ClinPlus Co. Ltd. yet.
SMO ClinPlus Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SMO ClinPlus Co. Ltd.
SMO ClinPlus CO.,LTD. provides site management services in research and development in pharmaceuticals, medical devices, and health-related products in China. It offers clinical trial site management organization services to pharmaceuticals, medical devices, CRO companies, etc. The company offers preliminary modeling and preparation plans, trial site initiation, on-site execution, and project management services. SMO ClinPlus CO.,LTD. was founded in 2009 and is based in Huan…
Full company profileSMO ClinPlus Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SMO ClinPlus Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 304M | 335M | 503M | 586M | 760M | 804M | 843M | 745M |
| Gross Profit | 99.8M | 97.7M | 131M | 160M | 231M | 196M | 218M | 76.4M |
| Operating Income | 61.1M | 46.9M | 73.3M | 79.3M | 155M | 115M | 134M | 3.92M |
| EBITDA | 62.4M | 49.2M | 73.9M | 89.5M | 172M | 135M | 144M | 8.43M |
| Net Income | 52.4M | 35.3M | 57.8M | 72.4M | 135M | 106M | 110M | 5.18M |
| EPS | 1.16 | 0.60 | 0.99 | 0.91 | 1.69 | 1.34 | 1.39 | 0.07 |
| Balance Sheet | ||||||||
| Total Assets | 202M | 292M | 404M | 1.16B | 1.37B | 1.43B | 1.54B | 1.53B |
| Total Liabilities | 76.7M | 127M | 175M | 209M | 286M | 256M | 274M | 264M |
| Shareholders' Equity | 125M | 165M | 229M | 952M | 1.08B | 1.17B | 1.27B | 1.27B |
| Cash & Short-term Investments | 89.6M | 103M | 136M | 677M | 493M | 489M | 467M | 331M |
| Cash Flow | ||||||||
| Operating Cash Flow | 45.5M | 22.4M | 41.5M | 40.4M | 115M | -1.07M | 35.7M | - |
| Capital Expenditure | 4.91M | 4.08M | 4.40M | 7.95M | 10.2M | 9.22M | 7.83M | 7.55M |
| Free Cash Flow | 40.6M | 18.4M | 37.1M | 32.5M | 105M | -10.3M | 27.9M | -68.6M |
| Ratios | ||||||||
| ROE | 41.8% | 21.4% | 25.2% | 7.6% | 12.5% | 9.1% | 8.6% | 0.4% |
| ROA | 25.9% | 12.1% | 14.3% | 6.2% | 9.9% | 7.4% | 7.1% | 0.3% |
| Net Profit Margin | 17.2% | 10.5% | 11.5% | 12.4% | 17.7% | 13.2% | 13.0% | 0.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SMO ClinPlus Co. Ltd. dividends
- Dividend yield
- 0.50%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 12.2%
- Ex-dividend date
- Jul 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 13.3M | 0.17 | 12.2% |
| 2024 | CNY 22.1M | 0.28 | 20.7% |
| 2023 | CNY 10.7M | 0.14 | 8.0% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | CNY 1.69K | 0.00 | 0.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jun 6, 2024.
Who owns SMO ClinPlus Co. Ltd.
- Insiders 42.70%
- Institutions 17.82%
- Public & others 39.48%
- Shares outstanding 79.0M
- Free float 44.0M
SMO ClinPlus Co. Ltd. company profile
- Company name
- SMO ClinPlus Co. Ltd.
- Ticker
- 301257.SHE
- ISIN
- CNE100005CP8
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4,372
- Fiscal year end
- December
- Address
- Shanghai World Trade Tower, Huangpu, China, 200001
- Phone
- 86 21 6075 5800
- Website
- smo-clinplus.com
About SMO ClinPlus Co. Ltd.
SMO ClinPlus CO.,LTD. provides site management services in research and development in pharmaceuticals, medical devices, and health-related products in China. It offers clinical trial site management organization services to pharmaceuticals, medical devices, CRO companies, etc. The company offers preliminary modeling and preparation plans, trial site initiation, on-site execution, and project management services. SMO ClinPlus CO.,LTD. was founded in 2009 and is based in Huangpu, China.
SMO ClinPlus Co. Ltd. management
7- Mr. Hongwei YangFounder, GM & Director · born 1977
- Ms. Weihong SongDirector of Finance & Accounting Supervisor · born 1971
- Mr. Xiaolong LaiBoard Secretary & Non-Independent Director · born 1972
- Ms. Xia ChenDeputy General Manager · born 1986
- Ms. Yue WangDeputy General Manager · born 1982
- Ms. Ting ChangDeputy General Manager · born 1983
- Ms. Jing ZhaoDeputy General Manager · born 1985